Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment Article Swipe
Related Concepts
Breast cancer
Tamoxifen
Oncology
Internal medicine
Hormone therapy
Chemotherapy
Medicine
Surgical oncology
Doxorubicin
Cancer
Hormone
Hormone receptor
Survival analysis
Wild type
Cancer research
Biology
Mutant
Gene
Genetics
Nathan Ungerleider
,
Sonia G. Rao
,
Ashkan Shahbandi
,
Douglas Yee
,
Tianhua Niu
,
Wesley D. Frey
,
James G. Jackson
·
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1186/s13058-018-1044-5
· OA: W2894491737
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1186/s13058-018-1044-5
· OA: W2894491737
The poor survival of chemotherapy-treated patients with TP53 wild-type tumors may be improved by strategies to eliminate senescent cells, including the addition of hormone therapy when appropriate.
Related Topics
Finding more related topics…